Yousef Zakharia, MD
Disclosures: Advisory; -Bayer|Advisory; -cardinal health|Consultant; -Eisai, Inc.|Advisory; -Novartis|Advisory; -Pfizer|Consultant; -TTC oncology|Accelovance, Inc.; Astellas Pharma Global Development, Inc.; AstraZeneca AB; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Bristol-Myers Squibb Pharmaceutical; Calithera BioSciences, Inc.; Clinical Professionals, Inc.; Clovis Oncology, Inc.; Eisai, Inc.; Exelixis, Inc.; Genentech, Inc.; MedImmune, LLC; Merck Sharp & Dohme Company; NewLink Genetics Corporation; Pfizer, Inc.; X4 Pharmaceuticals, Inc.-Sponsored Research|Accelovance, Inc.; Astellas Pharma Global Development, Inc.; AstraZeneca AB; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Calithera BioSciences, Inc.; Clinical Professionals, Inc.; Clovis Oncology, Inc.; Eisai, Inc.; Exelixis, Inc.; Genentech, Inc.; MedImmune, LLC; Merck Sharp & Dohme Company; NewLink Genetics Corporation; Pfizer, Inc.; X4 Pharmaceuticals, Inc.-Sponsored Research|Accelovance, Inc.; Astellas Pharma Global Development, Inc.; AstraZeneca AB; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Calithera BioSciences, Inc.; Clinical Professionals, Inc.; Clovis Oncology, Inc.; Eisai, Inc.; Exelixis, Inc.; Genentech, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; MedImmune, LLC; Merck Sharp & Dohme Company; NewLink Genetics Corporation; Pfizer, Inc.; X4 Pharmaceuticals, Inc.-Sponsored Research
No Bio Available.